Crossmark

miR-145-5p targets paxillin to attenuate angiotensin II-induced pathological cardiac hypertrophy via downregulation of Rac 1, pJNK, p-c-Jun, NFATc3, ANP and by Sirt-1 upregulation

Crossref DOI link: https://doi.org/10.1007/s11010-021-04100-w

Published Online: 2021-04-22

Published Print: 2021-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lin, Kuan-Ho

Kumar, V. Bharath

Shanmugam, Tamilselvi

Shibu, Marthandam Asokan

Chen, Ray-Jade

Kuo, Chia-Hua

Ho, Tsung-Jung

Padma, V. Vijaya

Yeh, Yu-Lan

Huang, Chih-Yang https://orcid.org/0000-0003-2347-0411
Funding

Funding for this research was provided by:

Ministry of Health and Welfare (MOHW107-TDU-B-212-123004)

China Medical University (DMR-109-059)
License Information

Text and Data Mining valid from 2021-04-22

Version of Record valid from 2021-04-22
More Information

Article History

Received: 20 October 2020

Accepted: 4 February 2021

First Online: 22 April 2021

Declarations

:

: All the authors declared that they have no conflict of interest.

Document is current

Any future updates will be listed below